Genomic markers for tumor proliferation assessed were AURKA, MYBL2, and MKI67. AURKA (N = 79) demonstrated a significant prognostic impact on DFS (HR 1.03, 95% CI 1.01-1.04) and OS (HR 1.02, 95% CI 1.01-1.04). Here, MYBL2 is linked to neoplasm.